HALEON

Haleon Pakistan Limited

By PSX Investors Zone · Updated October 24, 2026

Haleon Pakistan Limited company profile

Haleon Pakistan Limited (PSX: HALEON) is a listed consumer healthcare company manufacturing, marketing and selling over-the-counter health products in Pakistan. Formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited, it became part of the independent Haleon group following the consumer healthcare demerger. Its product portfolio includes well-known brands in pain relief, oral health, respiratory health and vitamins and supplements. For 2025, the company reported revenue of Rs43.106 billion, profit after tax of Rs6.373 billion and EPS of Rs54.45. Its latest reviewed 2026 quarterly results, for the quarter ended June 30, reported revenue of Rs10.072 billion and profit after tax of Rs1.676 billion. Haleon Pakistan was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published in May 2026, based on December 2025 financial statements. However, the official PSX profile displays a Risk Warning Alert concerning continuous exchange-rule violations and potential trading suspension or delisting. Investors should verify the latest exchange notices and Shariah screening before making decisions.

Haleon Pakistan Limited (PSX: HALEON) is a Pakistan Stock Exchange-listed consumer healthcare company engaged in the manufacturing, marketing and sale of consumer healthcare and over-the-counter (OTC) products. The company was incorporated on March 31, 2015, and its shares began trading on the Pakistan Stock Exchange on March 22, 2017.

Previously known as GlaxoSmithKline Consumer Healthcare Pakistan Limited, the company adopted the Haleon Pakistan Limited name in January 2023 following the separation of the global consumer healthcare business from GlaxoSmithKline plc. Haleon Pakistan is a subsidiary of Haleon Netherlands B.V., with Haleon plc as its ultimate parent.

Business Overview

Haleon Pakistan operates in the consumer healthcare market, serving consumers through products associated with pain relief, oral health, respiratory health, digestive health and vitamins, minerals and supplements.

Its portfolio includes established brands such as Panadol, Sensodyne, Voltral, Centrum and other consumer healthcare products. The business depends on brand recognition, product availability, manufacturing and distribution capabilities, pricing, regulatory compliance and consumer demand.

The company’s registered office is located at 11-A, 11th Floor, Sky Tower (East Wing), Dolmen City, Clifton, Karachi. Its official website is haleon.pk.

Financial Performance

Haleon Pakistan reported stronger annual revenue and profitability in 2025 compared with 2024.

Financial Metric20252024
RevenueRs43.106 billionRs37.206 billion
Gross profitRs16.852 billionRs12.819 billion
Operating profitRs10.682 billionRs7.714 billion
Profit after taxRs6.373 billionRs4.578 billion
Earnings per shareRs54.45Rs39.11

Revenue grew by approximately 15.9% year over year, while profit after tax increased by approximately 39.2%. The reported gross profit margin also improved, from approximately 34.45% in 2024 to 39.09% in 2025.

These figures indicate an improvement in reported financial performance during 2025. They do not establish that the same growth rate will continue. Investors should examine cost trends, pricing, sales volumes, taxation, cash flow and working-capital requirements when evaluating earnings quality.

Latest Reviewed 2026 Results

For the quarter ended June 30, 2026, the PSX company page reported revenue of approximately Rs10.072 billion, profit after tax of Rs1.676 billion and EPS of Rs14.32. For comparison, the quarter ended June 30, 2025, showed revenue of Rs11.598 billion, profit after tax of Rs1.623 billion and EPS of Rs13.87.

This represents lower year-over-year revenue but higher reported profit after tax for the quarter. These are quarterly figures, not full-year results. The reviewed PSX page listed a notice for a Q3 2026 board meeting dated October 21, 2026, but the Q3 results were not available in the results reviewed for this profile. Check the official PSX page for any subsequent results.

Source: Haleon Pakistan investor relations.

Dividend Information

The PSX announcements list a credit notice for an interim cash dividend dated September 17, 2026. Investors should consult the original dividend announcement and credit notice to confirm the per-share amount, eligibility dates and payment details before using the information for dividend calculations.

A dividend is not guaranteed to recur. Its sustainability depends on earnings, cash generation, capital requirements and the board’s decisions.

Official reference: PSX company profile and announcements.

Shariah Compliance Status

Haleon Pakistan Limited was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published on May 15, 2026. The screening was based on the latest available financial statements as of December 31, 2025.

The published screening ratios were:

  • Debt ratio: 0.92%
  • Non-compliant investment ratio: 12.25%
  • Non-compliant income ratio: 1.57%
  • Illiquid assets ratio: 62.82%

The classification reflects the screening methodology and financial information used for that review. It is not a guarantee of permanent compliance. Ratios and classifications may change as new financial statements become available or screening criteria are updated.

Investors who require Shariah-compliant investments should verify the latest official screening before buying, holding or selling shares.

Official source: PSX-KMI All Share Islamic Index recomposition — May 2026.

Important PSX Risk Warning

The official PSX profile displays the following Risk Warning Alert:

The Company is in continuous violation as specified in Clauses 5.11.1. or 5.11.2. and carry risk of suspension of trading or being delisted from the Exchange and may be subject to such terms and conditions as specified by the Exchange.

This warning concerns exchange compliance and the potential consequences for the company’s listing. It is a material consideration for investors and should not be overlooked because of the company’s brand portfolio or financial results.

Readers should review the latest PSX notices and company announcements to determine whether the warning remains in place and whether any relevant compliance action or subsequent update has been published.

Official reference: Haleon Pakistan Limited — PSX profile.

Key Factors Investors Should Monitor

  • Revenue and volume growth: changes in product sales, consumer demand and pricing.
  • Profit margins: movements in manufacturing costs, distribution expenses, marketing expenditure and taxation.
  • Brand and product portfolio: demand for established brands and the company’s ability to maintain availability and market position.
  • Regulatory requirements: compliance with applicable healthcare, manufacturing, labelling and product-registration requirements.
  • Cash flow and working capital: inventory levels, receivables, supplier payments and cash conversion.
  • Dividend sustainability: whether distributions remain supported by earnings and available cash.
  • Shariah screening: the latest PSX-KMI All Share Islamic Index status and ratios.
  • Exchange compliance: updates to the PSX Risk Warning Alert and any notices about possible trading suspension or delisting.

Frequently Asked Questions

What is Haleon Pakistan Limited’s PSX symbol?

The company trades on the Pakistan Stock Exchange under the symbol HALEON. Its former symbol was GSKCH.

Is Haleon Pakistan Shariah-compliant?

It was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published in May 2026, based on December 2025 financial statements. Investors should verify the latest official screening before relying on that classification.

What does Haleon Pakistan Limited do?

It manufactures, markets and sells consumer healthcare and OTC products, including products associated with pain relief, oral health, respiratory health and vitamins and supplements.

What were its FY2025 results?

For the year ended December 31, 2025, it reported revenue of Rs43.106 billion, profit after tax of Rs6.373 billion and EPS of Rs54.45.

Does Haleon Pakistan have a PSX risk warning?

Yes. The official PSX company page displays a Risk Warning Alert concerning continuous exchange-rule violations and the risk of suspension or delisting. Investors should check the latest official disclosures for updates.

Official Sources

This profile summarizes publicly available company and exchange information for investor education. Verify the latest financial results, dividend announcements, Shariah screening and PSX compliance notices before making investment decisions.

This profile is for educational purposes and is not a recommendation to buy or sell any security.

More company profiles

View all
IBLHL

Pharmaceuticals

IBL HealthCare Limited

IBL HealthCare Limited (PSX: IBLHL) is a Pakistani healthcare-products distribution and marketing company incorporated in 1997 and listed on the Pakistan Stock Exchange. Its principal activities include marketing, selling and distributing healthcare and pharmaceutical products across categories including nutrition, sweeteners and beverages, and medical and surgical disposables. The company is a subsidiary of The Searle Company Limited. In FY2026, IBL HealthCare reported revenue of Rs4.607 billion, profit after tax of Rs220.402 million and EPS of Rs2.24, compared with revenue of Rs4.322 billion and profit after tax of Rs208.371 million in FY2025. The board declared no cash dividend for FY2026. IBLHL was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published in May 2026, based on December 2025 financial data. Investors should also note that PSX currently displays a Risk Warning Alert concerning potential trading suspension or delisting, making the latest exchange notices essential reading.

HPL

Pharmaceuticals

Hoechst Pakistan Limited

Hoechst Pakistan Limited (PSX: HPL) is a Pakistan Stock Exchange-listed pharmaceutical company engaged in manufacturing, selling and trading pharmaceutical and related products. Incorporated in 1967, the company operates from Korangi Industrial Area, Karachi, and reports its financial results on a calendar-year basis. In FY2025, Hoechst Pakistan reported sales of Rs30.929 billion, profit after tax of Rs2.910 billion and EPS of Rs301.67, compared with sales of Rs26.748 billion and profit after tax of Rs1.857 billion in FY2024. For the quarter ended September 30, 2026, it reported sales of Rs7.790 billion, profit after tax of Rs614.346 million and EPS of Rs63.70. HPL was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published in May 2026, based on December 2025 financial statements. Investors should monitor quarterly profitability, product and regulatory developments, dividend sustainability and any changes in the company's latest Shariah screening status.

GLAXO

Pharmaceuticals

GlaxoSmithKline Pakistan Limited

GlaxoSmithKline Pakistan Limited (PSX: GLAXO) is a pharmaceutical company engaged in manufacturing and marketing research-based medicines and other pharmaceutical products in Pakistan. It is part of the global GSK group and operates across therapy areas including anti-infectives, dermatology, analgesics, and vaccines. For the year ended December 31, 2025, the company reported sales of approximately Rs65.90 billion, profit after tax of Rs10.03 billion, and earnings per share of Rs31.48. Its financial performance, product portfolio, manufacturing operations, regulatory environment, and cash-flow position are important factors for fundamental analysis. GLAXO was classified as Shariah-compliant in the PSX KMI All Share screening published in May 2026, based on financial statements available through December 2025. Investors should check subsequent screening updates before making decisions. **Important:** The official PSX company page displays a Risk Warning Alert stating that the company is in continuous violation of specified exchange clauses and carries a risk of trading suspension or delisting. Investors should review the latest PSX disclosures and understand this regulatory risk before evaluating the stock. Sources: [PSX company profile and financials](https://dps.psx.com.pk/company/GLAXO) | [GSK Pakistan](https://pk.gsk.com/en-pk/company/) | [PSX KMI screening notice](https://www.psx.com.pk/psx/files/?file=277899-1.pdf)